CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS
$100 million Strategic Transaction Closed Special Shareholder Dividend Funded Advancing Late Stage Clinical Pipeline NASHVILLE, Tenn., Aug. 4, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company, announced today its second...
Solo un extracto — este editor licencia su texto. Lea el comunicado completo en la fuente.
Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes


